Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 3106 AL 3120

Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer's Disease (AD)

Oh ES, Rosenberg PB, Rattinger GB, Stuart EA, Lyketsos CG, Leoutsakos JS.

J Am Geriatr Soc. 2021 Apr;69(4):955-963. doi: 10.1111/jgs.16970. Epub 2020 Dec 31.

Rhizoma Coptidis for Alzheimer's Disease and Vascular Dementia: A Literature Review

Wang Z, Yang Y, Liu M, Wei Y, Liu J, Pei H, Li H.

Curr Vasc Pharmacol. 2020;18(4):358-368. doi: 10.2174/1570161117666190710151545.

Is Ongoing Anticholinergic Burden Associated With Greater Cognitive Decline and Dementia Severity in Mild to Moderate Alzheimer's Disease?

Dyer AH, Murphy C, Segurado R, Lawlor B, Kennelly SP; NILVAD Study Group.

J Gerontol A Biol Sci Med Sci. 2020 Apr 17;75(5):987-994. doi: 10.1093/gerona/glz244.

A Pilot Study Comparing Effects of Bifrontal Versus Bitemporal Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Mild Alzheimer Disease

Liu CS, Herrmann N, Gallagher D, Rajji TK, Kiss A, Vieira D, Lanctôt KL.

J ECT. 2020 Sep;36(3):211-215. doi: 10.1097/YCT.0000000000000639.

Chromium picolinate attenuates cognitive deficit in ICV-STZ rat paradigm of sporadic Alzheimer's-like dementia via targeting neuroinflammatory and IRS-1/PI3K/AKT/GSK-3β pathway

Akhtar A, Dhaliwal J, Saroj P, Uniyal A, Bishnoi M, Sah SP.

Inflammopharmacology. 2020 Apr;28(2):385-400. doi: 10.1007/s10787-019-00681-7. Epub 2020 Jan 3.

Efficacy and Safety of Psychostimulants for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Kishi T, Sakuma K, Iwata N.

Pharmacopsychiatry. 2020 Apr;53(3):109-114. doi: 10.1055/a-1076-8228. Epub 2020 Jan 30.

Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial

Devanand DP, Andrews H, Kreisl WC, Razlighi Q, Gershon A, Stern Y, Mintz A, Wisniewski T, Acosta E, Pollina J, Katsikoumbas M, Bell KL, Pelton GH, Deliyannides D, Prasad KM, Huey ED.

BMJ Open. 2020 Feb 6;10(2):e032112. doi: 10.1136/bmjopen-2019-032112.

An evaluation of hydromethylthionine as a treatment option for Alzheimer's disease

Hashweh NN, Bartochowski Z, Khoury R, Grossberg GT.

Expert Opin Pharmacother. 2020 Apr;21(6):619-627. doi: 10.1080/14656566.2020.1719066. Epub 2020 Feb 8.

Impact of HMGB1, RAGE, and TLR4 in Alzheimer's Disease (AD): From Risk Factors to Therapeutic Targeting

Paudel YN, Angelopoulou E, Piperi C, Othman I, Aamir K, Shaikh MF.

Cells. 2020 Feb 7;9(2):383. doi: 10.3390/cells9020383.

The Interactions Between Alzheimer's Disease and Major Depression: Role of Ca(2+) Channel Blockers and Ca(2+)/cAMP Signalling

Bergantin LB.

Curr Drug Res Rev. 2020;12(2):97-102. doi: 10.2174/2589977512666200217093356.

Delaying memory decline: different options and emerging solutions

Schneider F, Horowitz A, Lesch KP, Dandekar T.

Transl Psychiatry. 2020 Jan 21;10(1):13. doi: 10.1038/s41398-020-0697-x.

Meditation treatment of Alzheimer disease and mild cognitive impairment: A protocol for systematic review

Chen Y, Zhang J, Zhang T, Cao L, You Y, Zhang C, Liu X, Zhang Q.

Medicine (Baltimore). 2020 Mar;99(10):e19313. doi: 10.1097/MD.0000000000019313.

Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease

Uddin MS, Kabir MT, Niaz K, Jeandet P, Clément C, Mathew B, Rauf A, Rengasamy KRR, Sobarzo-Sánchez E, Ashraf GM, Aleya L.

Molecules. 2020 Mar 11;25(6):1267. doi: 10.3390/molecules25061267.

One-Year Evaluation of a Targeted Medication Therapy Management Intervention for Older Adults

Martinez AI, Abner EL, Jicha GA, Rigsby DN, Eckmann LC, Huffmyer MJ, Moga DC.

J Manag Care Spec Pharm. 2020 Apr;26(4):520-528. doi: 10.18553/jmcp.2020.26.4.520.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias